Digest Network Come funziona
Network
/
Società
La
Non verificato

Lantern Pharma Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteTecnica

52 comunicati stampa

Guarda tutti i comunicati
29/04/2026
Industria
Sanità
Farmaceutica
Oncologia
Tecnica
Medicina - Varie
Scienza
Cardiologia
Biotecnologia
Management
Salute
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
24/04/2026
Web e Social Network
Eventi
Industria
Scienza
Tecnica
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
20/04/2026
Industria
Scienza
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
14/04/2026
Eventi
Industria
Software
Scienza
Farmaceutica
Oncologia
Information Technology
Tecnica
Biotecnologia
Salute
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
02/04/2026
Web e Social Network
Telefonia e Varie
Industria
Software
Scienza
Farmaceutica
Oncologia
Information Technology
Tecnica
Medicina - Varie
Biotecnologia
Salute
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
30/03/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Sanità
Scienza
Farmaceutica
Oncologia
Tecnica
Biotecnologia
Tecnologie Varie
Igiene alimentare
Salute
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
27/03/2026
Web e Social Network
Mercato del lavoro
Mercato azionario
Tecnica
Biotecnologia
Tecnologie Varie
Medicina - Varie
Salute
Farmaceutica
Oncologia
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
27/03/2026
Mercato del lavoro
Industria
Igiene alimentare
Tecnica
Farmaceutica
Medicina - Varie
Oncologia
Biotecnologia
Infanzia
Scienza
Vetrine/Shopping
Salute
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
23/03/2026
Web e Social Network
Finanza
Eventi
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Tecnica
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
23/03/2026
Web e Social Network
Finanza
Eventi
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Tecnica
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0